Q4 2024 Sedana Medical AB (publ) Earnings Call Transcript
Key Points
- Sedana Medical AB (STU:7D2A) achieved a new all-time high in sales for 2024, with a 17% growth, aligning with their increased sales guidance.
- The company successfully met the primary endpoint in both of their Phase III trials in the US, demonstrating non-inferiority and good safety results.
- Pediatric indication approval was received, allowing the use of inhaled sedation therapy for children aged 3 to 17 in nine countries, extending market protection for Sedaconda isoflurane by an additional year.
- The acquisition of their main supplier in Malaysia is expected to improve EBITDA by 2 percentage points once existing stock is depleted, contributing to long-term profitability.
- Sedana Medical AB (STU:7D2A) reported a stable gross margin of 71% for the full year, with a cash level of SEK194 million, indicating a slowdown in cash burn.
- Q4 sales growth was softer at 10%, despite being the best Q4 to date, indicating potential volatility in quarterly performance.
- Germany, the largest market, experienced flat growth due to turnover in the field force, highlighting sensitivity to organizational changes.
- The distributor markets saw a 28% decline in Q4 sales, reflecting inherent volatility and longer ordering cycles.
- The company still reported a small EBITDA loss of SEK1 million ex-US in Q4, despite improvements, indicating ongoing challenges in achieving consistent profitability.
- There are risks associated with the FDA approval process for the US market, including potential additional demands or questions from the FDA that could delay approval.
Hello and welcome to today's webcast with Sedana Medical. We have Johannes Doll, CEO; Johan Spetz, CFO; and Peter Sackey, CMO will present the year-end report for 2024. [Operator Instructions]
And with that said, I hand over the word to you guys.
()- -
Thank you very much. A warm welcome to Sedana Medical's Q4 and full year report 2024. Thank you very much for joining us today. Let's jump straight into the highlights on Page 3 please. This time it's even more of a pleasure to present our quarterly report to you, than usually and that is, because of the highlights on this page.
We have received the high-level results also now for our second pivotal trial in theUSnd they look great. We have met the primary endpoint, for both of our Phase III studies, both in the main analysis and across all supplementary and sensitivity analysis, and the safety looks good too. And of course it's too early to declare full victory here yet, but these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
